Ultrasound Guided Sacral Erector Spinae Plane Block in vNOTES Surgery
Ltrasound Guided Sacral Erector Spinae Plane Block in vNOTES Surgery
1 other identifier
interventional
42
0 countries
N/A
Brief Summary
Vaginal natural opening transendoscopic surgery (vNOTES) has emerged as a minimally invasive surgical approach in gynecological procedures. By utilizing the vaginal passage as a natural opening, vNOTES eliminates abdominal incisions and has been associated with less postoperative pain, shorter hospital stays, and faster recovery compared to traditional laparoscopic surgery. Despite these advantages, patients undergoing vNOTES may still experience significant perioperative pain due to visceral pelvic manipulation, colpotomy, and uterine traction during the procedure. Recently, sacral modification of ESP block has been described as a promising technique for surgeries involving sacral and perineal regions. Ultrasound-guided sacral ESP block has demonstrated beneficial postoperative analgesic effects in procedures such as pilonidal sinus surgery and other perineal operations. However, the potential role of sacral ESP block in gynecological procedures, particularly in vNOTES surgery, has not yet been sufficiently explored. Pelvic organs receive complex autonomic and somatic innervation, primarily originating from the sacral segments (S2-S4), including the pelvic splanchnic nerves and the pudendal nerve. Targeting these nerve pathways with sacral ESP block can provide effective analgesia for both the visceral and somatic components of pain associated with vNOTES procedures. Therefore, this prospective randomized study aimed to evaluate the effect of ultrasound-guided sacral erector spinae plane block on intraoperative opioid consumption in patients undergoing vNOTES surgery. It was hypothesized that adding sacral ESP block to general anesthesia would reduce intraoperative remifentanil requirements, lower postoperative pain scores, and decrease the amount of analgesics consumed postoperatively. The primary objective of this study was to investigate the effects of sacral ESP block on intraoperative opioid consumption in challenging vNOTES; the secondary objective was to determine its effects on postoperative pain scores and the amount of analgesics consumed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2026
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 24, 2026
CompletedStudy Start
First participant enrolled
July 25, 2026
CompletedFirst Posted
Study publicly available on registry
July 28, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 10, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 25, 2026
July 29, 2026
July 1, 2026
16 days
July 24, 2026
July 28, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
intraoperative remifentanil compsumtion
intraoperative period
Study Arms (2)
General anesthesia
ACTIVE COMPARATORIntraoperative remifentanil consumption will be recorded after standard general anesthesia induction. If heart rate and mean arterial pressure change by more than 20% from baseline, the remifentanil dose will be increased or decreased by 0.02-0.03 mcg/kg/min (Stepwise remifentanil titration protocol). Heart rate and mean arterial pressure values will be recorded during colpotomy and uterine traction. All patients will receive a standard analgesia protocol: 1 gram of paracetamol every 8 hours, 1 mg/kg of diclofenac every 12 hours, and 50 mg of tramadol as rescue analgesia if VAS \> 4. The total tramadol dose consumed will be recorded. Postoperative NRS scores at 0, 2, 6, 12, and 24 hours will be recorded (0: No pain, 10: Unbearable pain). Postoperative nausea, vomiting, and adverse events will also be recorded.
General anesthesia + Sacral ESP block
ACTIVE COMPARATORBilateral S2 level sacral ESP block will be performed under ultrasound guidance. A total of 20 ml of block solution will be administered to one side, consisting of 10 ml of 0.5% bupivacaine, 5 ml of 2% lidocaine, and 5 ml of saline. Intraoperative remifentanil consumption will be recorded after standard general anesthesia induction. If heart rate and mean arterial pressure change by more than 20% from baseline, the remifentanil dose will be increased or decreased by 0.02-0.03 mcg/kg/min (Stepwise remifentanil titration protocol). Heart rate and mean arterial pressure values will be recorded during colpotomy and uterine traction. All patients will receive a standard analgesia protocol: 1 gram of paracetamol every 8 hours, 1 mg/kg of diclofenac every 12 hours, and 50 mg of tramadol as rescue analgesia if VAS \> 4. The total tramadol dose consumed will be recorded. Postoperative NRS scores will be recorded at 0, 2, 6, 12, and 24 hours (0: No pain, 10: Unbearable pain). Postoperative nau
Interventions
Patients scheduled for vNOTES surgery will be divided into two groups: general anesthesia and general anesthesia + sacral ESP block. Intraoperative opioid consumption and other parameters of the patients will be recorded.
Eligibility Criteria
You may qualify if:
- Ages 18-65
- Planned for elective vNOTES surgery
- ASA 1-3
- BMI \<35
You may not qualify if:
- ASA 4
- Planned emergency surgery
- Pregnant patients
- Persons with coagulopathy
- Persons with allergy to local anesthetics
- Persons with neurological disease
- Persons with infection in the area where the block will be performed
- Persons who refuse to participate in the study for any reason
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Specialist
Study Record Dates
First Submitted
July 24, 2026
First Posted
July 28, 2026
Study Start
July 25, 2026
Primary Completion (Estimated)
August 10, 2026
Study Completion (Estimated)
August 25, 2026
Last Updated
July 29, 2026
Record last verified: 2026-07